CZ20022804A3 - Farmaceutický prostředek - Google Patents
Farmaceutický prostředek Download PDFInfo
- Publication number
- CZ20022804A3 CZ20022804A3 CZ20022804A CZ20022804A CZ20022804A3 CZ 20022804 A3 CZ20022804 A3 CZ 20022804A3 CZ 20022804 A CZ20022804 A CZ 20022804A CZ 20022804 A CZ20022804 A CZ 20022804A CZ 20022804 A3 CZ20022804 A3 CZ 20022804A3
- Authority
- CZ
- Czechia
- Prior art keywords
- receptor antagonist
- substance
- preparation
- magnesium
- injury
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 239000003890 substance P antagonist Substances 0.000 claims abstract description 34
- 208000029028 brain injury Diseases 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 150000002681 magnesium compounds Chemical class 0.000 claims abstract description 18
- 210000004556 brain Anatomy 0.000 claims abstract description 13
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 5
- 230000008764 nerve damage Effects 0.000 claims abstract description 5
- 208000020339 Spinal injury Diseases 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 31
- 208000014674 injury Diseases 0.000 claims description 30
- 208000027418 Wounds and injury Diseases 0.000 claims description 29
- 230000006378 damage Effects 0.000 claims description 28
- 239000002464 receptor antagonist Substances 0.000 claims description 19
- 229940044551 receptor antagonist Drugs 0.000 claims description 19
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- 102100024304 Protachykinin-1 Human genes 0.000 claims description 17
- 101800003906 Substance P Proteins 0.000 claims description 17
- 239000011777 magnesium Substances 0.000 claims description 16
- 229910052749 magnesium Inorganic materials 0.000 claims description 16
- 229940091250 magnesium supplement Drugs 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 13
- -1 FK88 Chemical compound 0.000 claims description 12
- 208000006752 brain edema Diseases 0.000 claims description 11
- 230000008499 blood brain barrier function Effects 0.000 claims description 10
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 9
- 230000035699 permeability Effects 0.000 claims description 9
- 230000007547 defect Effects 0.000 claims description 8
- 206010030113 Oedema Diseases 0.000 claims description 7
- 102100037346 Substance-P receptor Human genes 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 230000000982 vasogenic effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000003920 cognitive function Effects 0.000 claims description 5
- 230000007659 motor function Effects 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- CCIWVEMVBWEMCY-RCFOMQFPSA-N (2s)-1-[(3as,4s,7as)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one Chemical compound COC1=CC=CC=C1[C@H](C)C(=O)N1C[C@H](C(CC[C@@]2(O)C=3C(=CC=CC=3)OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[C@H]2C1 CCIWVEMVBWEMCY-RCFOMQFPSA-N 0.000 claims description 3
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 claims description 3
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 claims description 3
- 102100029409 Neuromedin-K receptor Human genes 0.000 claims description 3
- 102100037342 Substance-K receptor Human genes 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- FLNYLINBEZROPL-NSOVKSMOSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 FLNYLINBEZROPL-NSOVKSMOSA-N 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- 210000004126 nerve fiber Anatomy 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 108700023329 spantide II Proteins 0.000 claims description 2
- 108700032228 spantide III Proteins 0.000 claims description 2
- AZZJAARMZMEIHY-BBKUSFMUSA-N spantide ii Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N(C(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCCNC(=O)C=1C=NC=CC=1)C(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](N)CC=1C=C(Cl)C(Cl)=CC=1)C1=CC=CC=C1 AZZJAARMZMEIHY-BBKUSFMUSA-N 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000022306 Cerebral injury Diseases 0.000 claims 1
- 206010067275 Vasogenic cerebral oedema Diseases 0.000 claims 1
- 235000004213 low-fat Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 10
- 206010048962 Brain oedema Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 206010019196 Head injury Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229910001425 magnesium ion Inorganic materials 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- CWEISCOCKRHHOU-UJYVDGJVSA-N (2s)-n-[(2s)-1-amino-1-oxohexan-2-yl]-1-[(2r)-1-[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-benzamidopropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CCCC[C@@H](C(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C=2C=CC=CC=2)CCC1 CWEISCOCKRHHOU-UJYVDGJVSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FCDRFVCGMLUYPG-ROUUACIJSA-N (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CO[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 FCDRFVCGMLUYPG-ROUUACIJSA-N 0.000 description 2
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YTIHIRCOUAPRCS-YFKPBYRVSA-N (2s)-2-aminohexanamide Chemical compound CCCC[C@H](N)C(N)=O YTIHIRCOUAPRCS-YFKPBYRVSA-N 0.000 description 1
- GEMYTIALOXZOQO-IXOXMDGESA-N (2s,3s)-2-phenyl-n-[(5-propan-2-yl-2,3-dihydro-1-benzofuran-7-yl)methyl]piperidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1([C@@H]2NCCC[C@@H]2NCC=2C=3OCCC=3C=C(C=2)C(C)C)=CC=CC=C1 GEMYTIALOXZOQO-IXOXMDGESA-N 0.000 description 1
- FQSRZRILAZRGHC-UHFFFAOYSA-N 1,2,3,3a,5,6,7,7a-octahydroisoindol-4-one;hydrochloride Chemical compound Cl.O=C1CCCC2CNCC12 FQSRZRILAZRGHC-UHFFFAOYSA-N 0.000 description 1
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical compound O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 description 1
- KRFONXNOKMNVLZ-UHFFFAOYSA-N 18,20,27-triazaheptacyclo[15.11.0.03,15.04,12.07,11.019,27.021,26]octacosa-1(28),2,4(12),5,7(11),9,13,15,17,19,21,23,25-tridecaen-8-ol Chemical compound C1=CC=C2N(C=C3C(C=C4C=CC5=C(C4=C3)C=CC3=C5C=CC3O)=N3)C3=NC2=C1 KRFONXNOKMNVLZ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- FLNYLINBEZROPL-UHFFFAOYSA-N 2-benzhydryl-n-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 FLNYLINBEZROPL-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 description 1
- 150000005361 3-phenylpyridines Chemical class 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- MKLQPIYLZMLAER-UHFFFAOYSA-N 4-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CC=NC=N1 MKLQPIYLZMLAER-UHFFFAOYSA-N 0.000 description 1
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010072184 MEN 10627 Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108010086932 R 820 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- COWAAOSLGYXWBG-UHFFFAOYSA-N ethene;piperidine Chemical group C=C.C1CCNCC1 COWAAOSLGYXWBG-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000009427 motor defect Effects 0.000 description 1
- ZSAFRVVCZQRBQS-UHFFFAOYSA-N n-benzyl-2-(4-methylphenyl)pyridine-3-carboxamide Chemical class C1=CC(C)=CC=C1C1=NC=CC=C1C(=O)NCC1=CC=CC=C1 ZSAFRVVCZQRBQS-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- YBCYJDNOPAFFOW-XOAARHKISA-N win-62577 Chemical compound C1=CC=C2N(C=C3C(C=C4CC[C@@H]5[C@@H]([C@]4(C3)C)CC[C@]3([C@H]5CC[C@@]3(O)C#C)C)=N3)C3=NC2=C1 YBCYJDNOPAFFOW-XOAARHKISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ5146A AUPQ514600A0 (en) | 2000-01-18 | 2000-01-18 | Brain injury treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20022804A3 true CZ20022804A3 (cs) | 2002-11-13 |
Family
ID=3819274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20022804A CZ20022804A3 (cs) | 2000-01-18 | 2001-01-18 | Farmaceutický prostředek |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US6841551B2 (enExample) |
| EP (1) | EP1261335B1 (enExample) |
| JP (1) | JP4794794B2 (enExample) |
| KR (1) | KR100780119B1 (enExample) |
| CN (1) | CN1261095C (enExample) |
| AU (2) | AUPQ514600A0 (enExample) |
| BR (1) | BR0107695A (enExample) |
| CA (1) | CA2397723C (enExample) |
| CZ (1) | CZ20022804A3 (enExample) |
| DE (1) | DE60139244D1 (enExample) |
| HR (1) | HRP20020593B1 (enExample) |
| HU (1) | HUP0301920A3 (enExample) |
| IL (2) | IL150548A0 (enExample) |
| MX (1) | MXPA02007004A (enExample) |
| NO (1) | NO329320B1 (enExample) |
| NZ (2) | NZ534278A (enExample) |
| RU (1) | RU2276996C2 (enExample) |
| WO (1) | WO2001052844A1 (enExample) |
| YU (1) | YU54702A (enExample) |
| ZA (1) | ZA200205715B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| BRPI0407071B8 (pt) | 2003-01-28 | 2021-05-25 | Ironwood Pharmaceuticals Inc | peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais |
| GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
| US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| WO2006110118A1 (fr) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Produit cytoprotecteur |
| WO2006116634A2 (en) | 2005-04-26 | 2006-11-02 | Novadaq Technologies, Inc. | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
| US20060239921A1 (en) | 2005-04-26 | 2006-10-26 | Novadaq Technologies Inc. | Real time vascular imaging during solid organ transplant |
| WO2007016790A1 (en) * | 2005-08-10 | 2007-02-15 | Novadaq Technologies, Inc. | Intra-operative head & neck nerve mapping |
| US20070122344A1 (en) * | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
| US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
| US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
| US20080161744A1 (en) * | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
| US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
| DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| KR20100055430A (ko) * | 2007-07-19 | 2010-05-26 | 애들레이드 리서치 앤드 이노베이션 피티와이 리미티드 | 두개내압 감소 방법 |
| US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
| US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
| US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
| WO2009135178A2 (en) | 2008-05-02 | 2009-11-05 | Flower Robert W | Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| ES2657938T3 (es) | 2008-12-31 | 2018-03-07 | Ardelyx, Inc. | Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US8852566B2 (en) * | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
| US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| JP6154135B2 (ja) * | 2010-12-03 | 2017-06-28 | 国立大学法人 岡山大学 | 外傷性神経障害治療剤 |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| JP6028096B2 (ja) | 2012-06-21 | 2016-11-16 | ノバダック テクノロジーズ インコーポレイテッド | 血管造影及びかん流の定量化並びに解析手法 |
| EP2887964B1 (en) | 2012-08-21 | 2019-07-03 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014169094A2 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| BR112015032534B1 (pt) * | 2013-07-02 | 2020-03-03 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Uso de compostos ou sal ou solvato farmaceuticamente aceitável dos mesmos |
| BR112015032161A2 (pt) * | 2013-07-02 | 2017-07-25 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p |
| EP3016658A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iv |
| EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| WO2016049756A1 (en) | 2014-09-29 | 2016-04-07 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
| JP6487544B2 (ja) | 2014-10-09 | 2019-03-20 | ノバダック テクノロジーズ ユーエルシー | 蛍光媒介光電式容積脈波記録法を用いた組織中の絶対血流の定量化 |
| WO2018129557A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
| US11140305B2 (en) | 2017-02-10 | 2021-10-05 | Stryker European Operations Limited | Open-field handheld fluorescence imaging systems and methods |
| CA3149980A1 (en) * | 2019-08-23 | 2021-03-04 | Pierre Vankan | Therapeutic methods and uses thereof |
| WO2021202286A1 (en) * | 2020-03-30 | 2021-10-07 | Dignify Therapeutics, Llc | Compositions and methods for treating autonomic dysreflexia |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
| US4985896A (en) * | 1985-03-29 | 1991-01-15 | Canon Kabushiki Kaisha | Laser driving device |
| GB8929070D0 (en) * | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
| US4981744A (en) * | 1990-04-24 | 1991-01-01 | Swank Michael W | Non-planar expandable honeycomb structure |
| AU687754B2 (en) * | 1990-08-31 | 1998-03-05 | Warner-Lambert Company | Tachykinin antagonists |
| US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| AU4918796A (en) * | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
| AU5265596A (en) * | 1996-04-12 | 1997-11-07 | Neotech Medical Innovations, Inc. | Composition and method for the treatment of premenstrual syndrome |
| US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
| JP2001513562A (ja) * | 1997-08-28 | 2001-09-04 | メルク エンド カムパニー インコーポレーテッド | 月経前または黄体後期症候群の治療方法 |
| GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| PT1035115E (pt) | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
| CN1131212C (zh) | 1999-02-24 | 2003-12-17 | 弗·哈夫曼-拉罗切有限公司 | 苯基－和吡啶基衍生物 |
| PL350428A1 (en) | 1999-02-24 | 2002-12-16 | Hoffmann La Roche | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
| US6274588B1 (en) | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US6479433B1 (en) * | 2000-10-02 | 2002-11-12 | Smithers-Oasis Company | Polyurethane foam composites for grower applications and related methods |
-
2000
- 2000-01-18 AU AUPQ5146A patent/AUPQ514600A0/en not_active Abandoned
-
2001
- 2001-01-18 NZ NZ534278A patent/NZ534278A/en not_active IP Right Cessation
- 2001-01-18 CA CA2397723A patent/CA2397723C/en not_active Expired - Fee Related
- 2001-01-18 YU YU54702A patent/YU54702A/sh unknown
- 2001-01-18 EP EP01901048A patent/EP1261335B1/en not_active Expired - Lifetime
- 2001-01-18 HR HR20020593A patent/HRP20020593B1/xx not_active IP Right Cessation
- 2001-01-18 CN CNB018037208A patent/CN1261095C/zh not_active Expired - Fee Related
- 2001-01-18 AU AU26560/01A patent/AU782799B2/en not_active Expired
- 2001-01-18 KR KR1020027009218A patent/KR100780119B1/ko not_active Expired - Fee Related
- 2001-01-18 US US10/181,323 patent/US6841551B2/en not_active Expired - Fee Related
- 2001-01-18 HU HU0301920A patent/HUP0301920A3/hu unknown
- 2001-01-18 BR BR0107695-7A patent/BR0107695A/pt not_active IP Right Cessation
- 2001-01-18 DE DE60139244T patent/DE60139244D1/de not_active Expired - Fee Related
- 2001-01-18 JP JP2001552892A patent/JP4794794B2/ja not_active Expired - Fee Related
- 2001-01-18 MX MXPA02007004A patent/MXPA02007004A/es active IP Right Grant
- 2001-01-18 NZ NZ519990A patent/NZ519990A/en not_active IP Right Cessation
- 2001-01-18 WO PCT/AU2001/000046 patent/WO2001052844A1/en not_active Ceased
- 2001-01-18 IL IL15054801A patent/IL150548A0/xx unknown
- 2001-01-18 RU RU2002121640/15A patent/RU2276996C2/ru not_active IP Right Cessation
- 2001-01-18 CZ CZ20022804A patent/CZ20022804A3/cs unknown
-
2002
- 2002-07-02 IL IL150548A patent/IL150548A/en not_active IP Right Cessation
- 2002-07-17 ZA ZA200205715A patent/ZA200205715B/en unknown
- 2002-07-17 NO NO20023423A patent/NO329320B1/no not_active IP Right Cessation
-
2004
- 2004-12-21 US US11/017,978 patent/US20050107380A1/en not_active Abandoned
-
2009
- 2009-06-01 US US12/475,627 patent/US9186404B2/en not_active Expired - Lifetime
-
2015
- 2015-10-13 US US14/882,084 patent/US20160030474A1/en not_active Abandoned
-
2017
- 2017-09-25 US US15/714,819 patent/US10201568B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ20022804A3 (cs) | Farmaceutický prostředek | |
| US5902821A (en) | Use of carbazole compounds for the treatment of congestive heart failure | |
| US5576317A (en) | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis | |
| US20100184819A1 (en) | Method for reducing intracranial pressure | |
| JP2005534285A5 (ja) | 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法 | |
| KR101697801B1 (ko) | 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물 | |
| AU2019257493B2 (en) | Method for preventing and/or treating chronic traumatic encephalopathy-I | |
| Cristofori et al. | Vascular protection of lacidipine in salt-loaded Dahl-S rats at nonsustained antihypertensive doses | |
| HK1054872B (en) | Brain, spinal and nerve injury treatment | |
| PL203468B1 (pl) | Preparat do do zylnego lub domi esniowego leczenia uszkodzenia mózgu, rdzenia kr egowego i nerwów | |
| DE60305018T2 (de) | Citalopram zur behandlung von bluthochdruck | |
| Jasmin et al. | Prevention by cromakalim of spontaneously occurring cardiac necroses in polymyopathic hamsters |